Report Detail
Global Primary Biliary Cholangitis Treatment Market Growth (Status and Outlook) 2019-2024
- RnM3216322 |
- 30 March, 2019 |
- Global |
- 116 Pages |
- LPI(LP Information) |
- Other
Primary biliary cholangitis (PBC), previously known as primary biliary cirrhosis, is an autoimmune disease of the liver. It results from a slow, progressive destruction of the small bile ducts of the liver, causing bile and other toxins to build up in the liver, a condition called cholestasis. There's no cure for primary biliary cholangitis, but medications are available to help slow the progression of the disease and prevent complications. Options include: Ursodeoxycholic acid (UDCA) and Obeticholic acid (Ocaliva).
According to this study, over the next five years the Primary Biliary Cholangitis Treatment market will register a xx% CAGR in terms of revenue, the global market size will reach US$ xx million by 2024, from US$ xx million in 2019. In particular, this report presents the global revenue market share of key companies in Primary Biliary Cholangitis Treatment business, shared in Chapter 3.
This report presents a comprehensive overview, market shares and growth opportunities of Primary Biliary Cholangitis Treatment market by product type, application, key companies and key regions.
This study considers the Primary Biliary Cholangitis Treatment value generated from the sales of the following segments:
Segmentation by product type: breakdown data from 2014 to 2019 in Section 2.3; and forecast to 2024 in section 10.7.
Ursodeoxycholic Acid (UDCA)
Obeticholic Acid (Ocaliva)
Segmentation by application: breakdown data from 2014 to 2019, in Section 2.4; and forecast to 2024 in section 10.8.
Hospitals
Clinics
Others
This report also splits the market by region: Breakdown data in Chapter 4, 5, 6, 7 and 8.
Americas
United States
Canada
Mexico
Brazil
APAC
China
Japan
Korea
Southeast Asia
India
Australia
Europe
Germany
France
UK
Italy
Russia
Spain
Middle East & Africa
Egypt
South Africa
Israel
Turkey
GCC Countries
The report also presents the market competition landscape and a corresponding detailed analysis of the major vendor/manufacturers in the market. The key manufacturers covered in this report: Breakdown data in in Chapter 3.
Novartis
Bristol-Myers Squibb
Pfizer
GlaxoSmithKline
Teva Pharmaceutical
Retrophin
Lumena Pharmaceuticals
Intercept Pharmaceuticals
In addition, this report discusses the key drivers influencing market growth, opportunities, the challenges and the risks faced by key players and the market as a whole. It also analyzes key emerging trends and their impact on present and future development.
Research objectives
To study and analyze the global Primary Biliary Cholangitis Treatment market size by key regions/countries, product type and application, history data from 2014 to 2018, and forecast to 2024.
To understand the structure of Primary Biliary Cholangitis Treatment market by identifying its various subsegments.
Focuses on the key global Primary Biliary Cholangitis Treatment players, to define, describe and analyze the value, market share, market competition landscape, SWOT analysis and development plans in next few years.
To analyze the Primary Biliary Cholangitis Treatment with respect to individual growth trends, future prospects, and their contribution to the total market.
To share detailed information about the key factors influencing the growth of the market (growth potential, opportunities, drivers, industry-specific challenges and risks).
To project the size of Primary Biliary Cholangitis Treatment submarkets, with respect to key regions (along with their respective key countries).
To analyze competitive developments such as expansions, agreements, new product launches and acquisitions in the market.
To strategically profile the key players and comprehensively analyze their growth strategies.
Table of Contents
2019-2024 Global Primary Biliary Cholangitis Treatment Market Report (Status and Outlook)
1 Scope of the Report
- 1.1 Market Introduction
- 1.2 Research Objectives
- 1.3 Years Considered
- 1.4 Market Research Methodology
- 1.5 Economic Indicators
- 1.6 Currency Considered
2 Executive Summary
- 2.1 World Market Overview
- 2.1.1 Global Primary Biliary Cholangitis Treatment Market Size 2014-2024
- 2.1.2 Primary Biliary Cholangitis Treatment Market Size CAGR by Region
- 2.2 Primary Biliary Cholangitis Treatment Segment by Type
- 2.2.1 Ursodeoxycholic Acid (UDCA)
- 2.2.2 Obeticholic Acid (Ocaliva)
- 2.3 Primary Biliary Cholangitis Treatment Market Size by Type
- 2.3.1 Global Primary Biliary Cholangitis Treatment Market Size Market Share by Type (2014-2019)
- 2.3.2 Global Primary Biliary Cholangitis Treatment Market Size Growth Rate by Type (2014-2019)
- 2.4 Primary Biliary Cholangitis Treatment Segment by Application
- 2.4.1 Hospitals
- 2.4.2 Clinics
- 2.4.3 Others
- 2.5 Primary Biliary Cholangitis Treatment Market Size by Application
- 2.5.1 Global Primary Biliary Cholangitis Treatment Market Size Market Share by Application (2014-2019)
- 2.5.2 Global Primary Biliary Cholangitis Treatment Market Size Growth Rate by Application (2014-2019)
3 Global Primary Biliary Cholangitis Treatment by Players
- 3.1 Global Primary Biliary Cholangitis Treatment Market Size Market Share by Players
- 3.1.1 Global Primary Biliary Cholangitis Treatment Market Size by Players (2017-2019)
- 3.1.2 Global Primary Biliary Cholangitis Treatment Market Size Market Share by Players (2017-2019)
- 3.2 Global Primary Biliary Cholangitis Treatment Key Players Head office and Products Offered
- 3.3 Market Concentration Rate Analysis
- 3.3.1 Competition Landscape Analysis
- 3.3.2 Concentration Ratio (CR3, CR5 and CR10) (2017-2019)
- 3.4 New Products and Potential Entrants
- 3.5 Mergers & Acquisitions, Expansion
4 Primary Biliary Cholangitis Treatment by Regions
- 4.1 Primary Biliary Cholangitis Treatment Market Size by Regions
- 4.2 Americas Primary Biliary Cholangitis Treatment Market Size Growth
- 4.3 APAC Primary Biliary Cholangitis Treatment Market Size Growth
- 4.4 Europe Primary Biliary Cholangitis Treatment Market Size Growth
- 4.5 Middle East & Africa Primary Biliary Cholangitis Treatment Market Size Growth
5 Americas
- 5.1 Americas Primary Biliary Cholangitis Treatment Market Size by Countries
- 5.2 Americas Primary Biliary Cholangitis Treatment Market Size by Type
- 5.3 Americas Primary Biliary Cholangitis Treatment Market Size by Application
- 5.4 United States
- 5.5 Canada
- 5.6 Mexico
- 5.7 Key Economic Indicators of Few Americas Countries
6 APAC
- 6.1 APAC Primary Biliary Cholangitis Treatment Market Size by Countries
- 6.2 APAC Primary Biliary Cholangitis Treatment Market Size by Type
- 6.3 APAC Primary Biliary Cholangitis Treatment Market Size by Application
- 6.4 China
- 6.5 Japan
- 6.6 Korea
- 6.7 Southeast Asia
- 6.8 India
- 6.9 Australia
- 6.10 Key Economic Indicators of Few APAC Countries
7 Europe
- 7.1 Europe Primary Biliary Cholangitis Treatment by Countries
- 7.2 Europe Primary Biliary Cholangitis Treatment Market Size by Type
- 7.3 Europe Primary Biliary Cholangitis Treatment Market Size by Application
- 7.4 Germany
- 7.5 France
- 7.6 UK
- 7.7 Italy
- 7.8 Russia
- 7.9 Spain
- 7.10 Key Economic Indicators of Few Europe Countries
8 Middle East & Africa
- 8.1 Middle East & Africa Primary Biliary Cholangitis Treatment by Countries
- 8.2 Middle East & Africa Primary Biliary Cholangitis Treatment Market Size by Type
- 8.3 Middle East & Africa Primary Biliary Cholangitis Treatment Market Size by Application
- 8.4 Egypt
- 8.5 South Africa
- 8.6 Israel
- 8.7 Turkey
- 8.8 GCC Countries
9 Market Drivers, Challenges and Trends
- 9.1 Market Drivers and Impact
- 9.1.1 Growing Demand from Key Regions
- 9.1.2 Growing Demand from Key Applications and Potential Industries
- 9.2 Market Challenges and Impact
- 9.3 Market Trends
10 Global Primary Biliary Cholangitis Treatment Market Forecast
- 10.1 Global Primary Biliary Cholangitis Treatment Market Size Forecast (2019-2024)
- 10.2 Global Primary Biliary Cholangitis Treatment Forecast by Regions
- 10.2.1 Global Primary Biliary Cholangitis Treatment Forecast by Regions (2019-2024)
- 10.2.2 Americas Market Forecast
- 10.2.3 APAC Market Forecast
- 10.2.4 Europe Market Forecast
- 10.2.5 Middle East & Africa Market Forecast
- 10.3 Americas Forecast by Countries
- 10.3.1 United States Market Forecast
- 10.3.2 Canada Market Forecast
- 10.3.3 Mexico Market Forecast
- 10.3.4 Brazil Market Forecast
- 10.4 APAC Forecast by Countries
- 10.4.1 China Market Forecast
- 10.4.2 Japan Market Forecast
- 10.4.3 Korea Market Forecast
- 10.4.4 Southeast Asia Market Forecast
- 10.4.5 India Market Forecast
- 10.4.6 Australia Market Forecast
- 10.5 Europe Forecast by Countries
- 10.5.1 Germany Market Forecast
- 10.5.2 France Market Forecast
- 10.5.3 UK Market Forecast
- 10.5.4 Italy Market Forecast
- 10.5.5 Russia Market Forecast
- 10.5.6 Spain Market Forecast
- 10.6 Middle East & Africa Forecast by Countries
- 10.6.1 Egypt Market Forecast
- 10.6.2 South Africa Market Forecast
- 10.6.3 Israel Market Forecast
- 10.6.4 Turkey Market Forecast
- 10.6.5 GCC Countries Market Forecast
- 10.7 Global Primary Biliary Cholangitis Treatment Forecast by Type
- 10.8 Global Primary Biliary Cholangitis Treatment Forecast by Application
11 Key Players Analysis
- 11.1 Novartis
- 11.1.1 Company Details
- 11.1.2 Primary Biliary Cholangitis Treatment Product Offered
- 11.1.3 Novartis Primary Biliary Cholangitis Treatment Revenue, Gross Margin and Market Share (2017-2019)
- 11.1.4 Main Business Overview
- 11.1.5 Novartis News
- 11.2 Bristol-Myers Squibb
- 11.2.1 Company Details
- 11.2.2 Primary Biliary Cholangitis Treatment Product Offered
- 11.2.3 Bristol-Myers Squibb Primary Biliary Cholangitis Treatment Revenue, Gross Margin and Market Share (2017-2019)
- 11.2.4 Main Business Overview
- 11.2.5 Bristol-Myers Squibb News
- 11.3 Pfizer
- 11.3.1 Company Details
- 11.3.2 Primary Biliary Cholangitis Treatment Product Offered
- 11.3.3 Pfizer Primary Biliary Cholangitis Treatment Revenue, Gross Margin and Market Share (2017-2019)
- 11.3.4 Main Business Overview
- 11.3.5 Pfizer News
- 11.4 GlaxoSmithKline
- 11.4.1 Company Details
- 11.4.2 Primary Biliary Cholangitis Treatment Product Offered
- 11.4.3 GlaxoSmithKline Primary Biliary Cholangitis Treatment Revenue, Gross Margin and Market Share (2017-2019)
- 11.4.4 Main Business Overview
- 11.4.5 GlaxoSmithKline News
- 11.5 Teva Pharmaceutical
- 11.5.1 Company Details
- 11.5.2 Primary Biliary Cholangitis Treatment Product Offered
- 11.5.3 Teva Pharmaceutical Primary Biliary Cholangitis Treatment Revenue, Gross Margin and Market Share (2017-2019)
- 11.5.4 Main Business Overview
- 11.5.5 Teva Pharmaceutical News
- 11.6 Retrophin
- 11.6.1 Company Details
- 11.6.2 Primary Biliary Cholangitis Treatment Product Offered
- 11.6.3 Retrophin Primary Biliary Cholangitis Treatment Revenue, Gross Margin and Market Share (2017-2019)
- 11.6.4 Main Business Overview
- 11.6.5 Retrophin News
- 11.7 Lumena Pharmaceuticals
- 11.7.1 Company Details
- 11.7.2 Primary Biliary Cholangitis Treatment Product Offered
- 11.7.3 Lumena Pharmaceuticals Primary Biliary Cholangitis Treatment Revenue, Gross Margin and Market Share (2017-2019)
- 11.7.4 Main Business Overview
- 11.7.5 Lumena Pharmaceuticals News
- 11.8 Intercept Pharmaceuticals
- 11.8.1 Company Details
- 11.8.2 Primary Biliary Cholangitis Treatment Product Offered
- 11.8.3 Intercept Pharmaceuticals Primary Biliary Cholangitis Treatment Revenue, Gross Margin and Market Share (2017-2019)
- 11.8.4 Main Business Overview
- 11.8.5 Intercept Pharmaceuticals News
12 Research Findings and Conclusion
Summary:
Get latest Market Research Reports on Primary Biliary Cholangitis Treatment . Industry analysis & Market Report on Primary Biliary Cholangitis Treatment is a syndicated market report, published as Global Primary Biliary Cholangitis Treatment Market Growth (Status and Outlook) 2019-2024. It is complete Research Study and Industry Analysis of Primary Biliary Cholangitis Treatment market, to understand, Market Demand, Growth, trends analysis and Factor Influencing market.
REPORT YOU MIGHT BE INTERESTED
Related Reports
Reason to Buy
Reports and Markets
Contact Us
+1-352-353-0818 (US)Newsletter
KEEP UP TO DATE ON ALL THE LATEST REPORTS
